202. Smith-Magenis syndrome Clinical trials / Disease details
Clinical trials : 9 / Drugs : 10 - (DrugBank : 5) / Drug target genes : 4 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03492970 (ClinicalTrials.gov) | March 7, 2018 | 1/3/2018 | Melatonin in Adults With SMS | Characterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis Syndrome | Smith Magenis Syndrome | Biological: Hourly dosing of the nychtemeral secretion of melatonin | Hôpital le Vinatier | Hospices Civils de Lyon | Completed | 18 Years | 65 Years | All | 10 | N/A | France |
| 2 | NCT00506259 (ClinicalTrials.gov) | July 17, 2007 | 21/7/2007 | Treatment Strategies for Children With Smith-Magenis Syndrome | A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) | Developmental Delay Disorders;Chromosome Deletion;Mental Retardation;Sleep Disorders, Circadian Rhythm;Self Injurious Behavior | Drug: dTR Melatonin (NIH CC PDS);Device: Phototherapy (Bright Light);Drug: Melatonin CR | National Human Genome Research Institute (NHGRI) | NULL | Completed | 3 Years | 45 Years | All | 23 | Phase 1 | United States |
| 3 | NCT00691574 (ClinicalTrials.gov) | September 1998 | 30/5/2008 | Melatonin Levels in Smith Magenis Syndrome (SMS) | Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot Study | Chromosome Disorders | Dietary Supplement: Melatonin;Device: Enviro-light artificial light box | Oregon Health and Science University | NULL | Terminated | 3 Years | 85 Years | All | 5 | N/A | United States |